Supplemental material
Drug Delivery
Volume 24, 2017 - Issue 1
Related Research Data
Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer
Source:
Impact Journals, LLC
Dendritic cell-based therapeutic cancer vaccines: past, present and future.
Source:
Korean Vaccine Society (KAMJE)
MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS
Source:
Annual Reviews
Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA
Source:
Oxford University Press (OUP)
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Source:
Massachusetts Medical Society
Construction of novel multifunctional luminescent nanoparticles based on DNA bridging and their inhibitory effect on tumor growth
Source:
Royal Society of Chemistry (RSC)
A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo
Source:
Figshare
Cyclodextrin and Polyethylenimine Functionalized Mesoporous Silica Nanoparticles for Delivery of siRNA Cancer Therapeutics
Source:
Ivyspring International Publisher
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.
Source:
American Chemical Society (ACS)
Delivery of Therapeutic siRNA to the Lung Endothelium via Novel Lipoplex Formulation DACC
Source:
Elsevier BV
Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Source:
Informa UK Limited
Optimization of RGD-containing cyclic peptides against αvβ3 integrin
Source:
American Association for Cancer Research (AACR)
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Source:
Massachusetts Medical Society
Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release.
Source:
Informa UK Limited
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Source:
Springer Science and Business Media LLC
High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics.
Source:
American Chemical Society (ACS)
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.
Source:
Springer Science and Business Media LLC
Multivalent Cyclic RGD Conjugates for Targeted Delivery of Small Interfering RNA
Source:
The University of North Carolina at Chapel Hill University Libraries
Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR
Source:
Springer Science and Business Media LLC
INTEGRINS AND THE KIDNEY : BIOLOGY AND PATHOBIOLOGY
Source:
Ovid Technologies (Wolters Kluwer Health)
Design of siRNA Therapeutics from the Molecular Scale
Source:
MDPI AG
Delivery materials for siRNA therapeutics
Source:
Springer Science and Business Media LLC
Therapeutic cancer vaccines: past, present, and future.
Source:
Elsevier
Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond.
Source:
Springer Science and Business Media LLC
In vivo toxicity of cationic micelles and liposomes.
Source:
The Authors. Published by Elsevier Ltd.
Linking provided by
